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OBJECTIVES: This study focuses on the effects of thymoquinone on isolated arteries, by 
determining the mechanisms underlying the endothelium- and soluble guanylyl cyclase 
(sGC)-dependent augmentation of contraction that this natural compound causes, 
comparable to the augmentation described under hypoxic conditions. METHODS: 
Experiments were designed to study the effect of thymoquinone ex vivo in isolated 
porcine coronary and rat arteries. Rings, with or without endothelium, were suspended in 
conventional organ chambers for isometric tension recording. Certain rings were 
incubated with inhibitors of nitric oxide (NO) synthase (L-NG-nitroarginine methyl ester, 
LNAME), sGC (1H-[1,2, 4]oxadiazolo[4,3-a]quinoxalin-1-one, ODQ), rhoassociated 
protein kinases (Y-27632) or L-type voltage-gated calcium channels (nifedipine). Some 
of the control experiments were done under depleted calcium conditions. The rings were 
contracted with phenylephrine (rat arteries) or prostaglandin F2α (porcine coronaries) and 
exposed to increasing concentrations of thymoquinone. Selected rings were used to 
measure cyclic nucleotide levels by HPLC-MS/MS. RESULTS: Thymoquinone caused a 
sustained further increase in tension in rings with endothelium. This augmentation was 
prevented by endotheliumremoval, L-NAME and ODQ. Incubation with the NO-donor 
DETA NONOate in L-NAME-treated rings restored and even increased the contractile 
response to thymoquinone. Treatment with 8-bromo guanosine 3':5' cyclic 
monophosphate (cyclic GMP) or pyrophospate did not restore the augmentation by 
thymoquinone. HPLC-MS/MS measurements revealed that the compound increased the 
production of inosine 3':5' cyclic monophosphate (cyclic IMP). Y-27632, nifedipine and 
calcium depletion inhibited the thymoquinone-induced contraction in porcine coronary 
arteries, but not in rat aortae. CONCLUSIONS: The endothelium-dependent 
augmentation caused by thymoquinone requires endothelium-derived NO and activation 
of sGC, as described under hypoxic conditions. In addition, both thymoquinone- and 
hypoxiainduced augmentations require production of cyclic IMP but not the presence of 
either pyrophosphate or cyclic GMP. The data suggest that cyclic IMP causes 
vasoconstriction through calcium sensitization, although the underlying mechanism 
seems to differ in rat and porcine arteries. Taken into conjunction, thymoquinone can 
serve as a pharmacological tool to study/ mimic the endothelium-dependent 
vasoconstrictor effects of intermittent hypoxia, as seen in the clinical setting of sleep 
apnea patients. 
